A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer

Summary

The main purpose of this study is to evaluate the effectiveness of the study drug known as abemaciclib versus docetaxel in participants with stage IV squamous non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy.

Timeline

Start

2015-08-06

Primary completion

2017-03-31

Completion

2020-07-29

Outcome

Missed primary endpoint

registry analysis (superiority test); Abemaciclib vs Docetaxel; p = 0.0068; Hazard Ratio (HR) 1.765 (95% CI 1.165 to 2.672); Stratified log-rank test. NCT02450539 ↗

Drugs

Indications